Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of IV formulation of Selonabant for unintentional cannabis poisoning in childeren

Trial Profile

A clinical trial of IV formulation of Selonabant for unintentional cannabis poisoning in childeren

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selonabant (Primary)
  • Indications Substance-related disorders
  • Focus Adverse reactions

Most Recent Events

  • 03 Oct 2024 New trial record
  • 25 Sep 2024 According to an Anebulo Pharmaceuticals media release, the Company expects to enroll the first healthy adult volunteer in the first half of calendar 2025.
  • 25 Sep 2024 According to an Anebulo Pharmaceuticals media release, the company has received the first tranche of a two year cooperative grant of up to approximately 1.9 million Dollars from the National Institute on Drug Abuse (NIDA), part of the NIH. With this support from NIDA, Anebulo aims to complete IND-enabling activities and the scale up of its IV formulation of selonabant around calendar year end 2024 as it prepares for clinical studies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top